Luc Verhees is Senior Vice President for Clinical, Pre-Clinical and Medical Affairs at Xeltis. He joined the company as Vice President for Clinical Affairs in January 2018, bringing a 25-year experience in cardiovascular clinical research, training and education, medical affairs and business development in Europe and in the USA.
Prior to Xeltis, he was Vice President for Global Clinical Affairs at LivaNova, the 2015 merger result between Sorin and Cyberonics. There, he was responsible for the global clinical affairs strategy and execution of all clinical trials in the field of Cardiac Rhythm Management (CRM), Cardiac Surgery and Neuromodulation.
Verhees previously held several management positions at Medtronic and Boston Scientific, as well as at start-up companies such as Spectranetics, Novoste and Corevalve, focusing on new and breakthrough technologies within interventional cardiology, cardiac surgery and peripheral interventions. For 11 years prior to that, he was a hospital-based healthcare professional.